CYCCCyclacel Pharmaceuticals, Inc.

Nasdaq cyclacel.com


$ 2.48 $ -0.40 (-14.08 %)    

Wednesday, 15-May-2024 15:52:41 EDT
QQQ $ 452.83 $ 3.91 (0.87 %)
DIA $ 399.31 $ 3.70 (0.94 %)
SPY $ 529.09 $ 3.17 (0.6 %)
TLT $ 92.14 $ 1.28 (1.41 %)
GLD $ 220.89 $ 2.80 (1.28 %)
$ 2.44
$ 2.61
$ 0.00 x 0
$ 0.00 x 0
$ 2.34 - $ 2.64
$ 1.30 - $ 13.20
164,107
na
3.57M
$ 1.33
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-21-2024 12-31-2023 10-K
3 11-29-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-08-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-30-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-14-2021 03-31-2021 10-Q
14 03-01-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-13-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-05-2020 12-31-2019 10-K
19 11-13-2019 09-30-2019 10-Q
20 08-13-2019 06-30-2019 10-Q
21 05-14-2019 03-31-2019 10-Q
22 03-28-2019 12-31-2018 10-K
23 11-13-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-14-2018 03-31-2018 10-Q
26 03-30-2018 12-31-2017 10-K
27 11-13-2017 09-30-2017 10-Q
28 08-10-2017 06-30-2017 10-Q
29 05-12-2017 03-31-2017 10-Q
30 03-31-2017 12-31-2016 10-K
31 11-14-2016 09-30-2016 10-Q
32 08-11-2016 06-30-2016 10-Q
33 05-13-2016 03-31-2016 10-Q
34 03-29-2016 12-31-2015 10-K
35 11-12-2015 09-30-2015 10-Q
36 08-12-2015 06-30-2015 10-Q
37 05-12-2015 03-31-2015 10-Q
38 03-31-2015 12-31-2014 10-K
39 11-12-2014 09-30-2014 10-Q
40 08-12-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cyclacel-pharmaceuticals-q1-eps-227-beats-474-estimate-sales-2900k

Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(2.27) per share which beat the analyst consensus estimate...

 roth-mkm-maintains-buy-on-cyclacel-pharmaceuticals-lowers-price-target-to-11

Roth MKM analyst Jonathan Aschoff maintains Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a Buy and lowers the price target fr...

Core News & Articles
Market-Moving News for April 30th
04/30/2024 12:45:17

MMM: 8.3% | 3M shares are trading higher following a Q1 earnings beat, reversing after initially falling. CYCC: 103% | Cyclace...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION